This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Myoui, A. Articles by Yoneda, T. Search for Related Content PubMed PubMed Citation Articles by Myoui, A. Articles by Yoneda, T.

C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis¹

Osaka University, Graduate School of Medicine, Department of Orthopaedics [A. M., D. T.], Graduate School of Dentistry, Department of Biochemistry [R. N., T. H., D. T., T. Y.], Suita, Osaka 565-0871, Japan; Department of Environmental Medicine, Osaka Medical Center and Institute for Maternal and Child Health, Izumi, Osaka 594-1101, Japan [T. M.]; and The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Endocrinology and Metabolism, San Antonio, Texas 78229-3900 [P. J. W., G. R. M., T. Y.]

The proto-oncogene, c-src, has been implicated in the tumorigenesis in breast cancer. However, the relationship of c-src with distant metastasis is unclear. Moreover, the role of c-src in organ-preferential metastasis of breast cancer is unknown. Because breast cancer has a strong predilection for metastasizing to bone, we examined the role of c-src in bone metastases using an animal model in which inoculation of the MDA-231 human breast cancer cells into the left cardiac ventricle preferentially developed osteolytic bone metastases in female nude mice. A clone of the MDA-231 with the increased capacity of bone metastasis exhibited elevated c-src tyrosine kinase (TK) activity compared with parental cells. MDAsrc527 cells caused significantly increased size of the osteolytic bone metastases with increased number of osteoclasts and mitotic cancer cells compared with MDA-231EV or MDAsrcWT. In contrast, MDAsrc295 cells caused impaired metastases to bone. Of note, mice inoculated with MDAsrc295 cells via tail vein developed reduced lung metastases and prolonged survival compared with mice with MDA-231EV cells, suggesting that c-src TK is unlikely to play a specific role in bone metastases. The growth in vitro and in vivo and production of parathyroid hormone-related protein, a key cytokine in the pathogenesis of osteolytic bone metastases in breast cancer, were promoted in MDAsrc527 and diminished in MDAsrc295. These results suggest that c-src TK is associated with the capacity of breast cancer to metastasize to bone through regulating cell growth and parathyroid hormone-related protein production. Our results together with the fact that c-src is an essential molecule for bone resorption by osteoclasts, which are central players in osteolytic bone metastases, support the notion that c-src TK is a potential target molecule for designing novel therapeutic interventions, especially for bone metastases in breast cancer.

This article has been cited by other articles:

				T. Akiyama, C. R. Dass, and P. F.M. Choong Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway Mol. Cancer Ther., November 1, 2008; 7(11): 3461 - 3469. [Abstract] [Full Text] [PDF]

				R. S. Finn Targeting Src in breast cancer Ann. Onc., August 1, 2008; 19(8): 1379 - 1386. [Abstract] [Full Text] [PDF]

				P. Koppikar, S.-H. Choi, A. M. Egloff, Q. Cai, S. Suzuki, M. Freilino, H. Nozawa, S. M. Thomas, W. E. Gooding, J. M. Siegfried, et al. Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4284 - 4291. [Abstract] [Full Text] [PDF]

				E. J. Wasserman and A. R. Tan Evolving Strategies for the Treatment of "Triple-Negative" Breast Cancer ASCO Educational Book, January 1, 2008; 2008(1): 120 - 126. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				E. Matteucci, E. Ridolfi, P. Maroni, P. Bendinelli, and M. A. Desiderio c-Src/Histone Deacetylase 3 Interaction Is Crucial for Hepatocyte Growth Factor Dependent Decrease of CXCR4 Expression in Highly Invasive Breast Tumor Cells Mol. Cancer Res., August 1, 2007; 5(8): 833 - 845. [Abstract] [Full Text] [PDF]

				R. P. Carnevale, C. J. Proietti, M. Salatino, A. Urtreger, G. Peluffo, D. P. Edwards, V. Boonyaratanakornkit, E. H. Charreau, E. B. de Kier Joffe, R. Schillaci, et al. Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways Mol. Endocrinol., June 1, 2007; 21(6): 1335 - 1358. [Abstract] [Full Text] [PDF]

				F. Huang, K. Reeves, X. Han, C. Fairchild, S. Platero, T. W. Wong, F. Lee, P. Shaw, and E. Clark Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection Cancer Res., March 1, 2007; 67(5): 2226 - 2238. [Abstract] [Full Text] [PDF]

				H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1580 - 1588. [Abstract] [Full Text] [PDF]

				N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, M. Bologna, and A. Teti Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 161 - 172. [Abstract] [Full Text] [PDF]

				V. V. Artym, Y. Zhang, F. Seillier-Moiseiwitsch, K. M. Yamada, and S. C. Mueller Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res., March 15, 2006; 66(6): 3034 - 3043. [Abstract] [Full Text] [PDF]

				J. Qi, J. Wang, O. Romanyuk, and C.-H. Siu Involvement of Src Family Kinases in N-Cadherin Phosphorylation and beta-Catenin Dissociation during Transendothelial Migration of Melanoma Cells Mol. Biol. Cell, March 1, 2006; 17(3): 1261 - 1272. [Abstract] [Full Text] [PDF]

				G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]

				R. Karni, Y. Gus, Y. Dor, O. Meyuhas, and A. Levitzki Active Src Elevates the Expression of {beta}-Catenin by Enhancement of Cap-Dependent Translation Mol. Cell. Biol., June 15, 2005; 25(12): 5031 - 5039. [Abstract] [Full Text] [PDF]

				J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]

				K. Liu, S. A. Caldwell, and S. I. Abrams Cooperative Disengagement of Fas and Intercellular Adhesion Molecule-1 Function in Neoplastic Cells Confers Enhanced Colonization Efficiency Cancer Res., February 1, 2005; 65(3): 1045 - 1054. [Abstract] [Full Text] [PDF]

				M. V. Yezhelyev, G. Koehl, M. Guba, T. Brabletz, K.-W. Jauch, A. Ryan, A. Barge, T. Green, M. Fennell, and C. J. Bruns Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., December 1, 2004; 10(23): 8028 - 8036. [Abstract] [Full Text] [PDF]

				Y.-P. Lim, C. Y. Wong, L. L. Ooi, B. J. Druker, and R. J. Epstein Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers: Implications for Adjuvant Use of Kinase-Inhibitory Drugs Clin. Cancer Res., June 15, 2004; 10(12): 3980 - 3987. [Abstract] [Full Text] [PDF]